지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
This article discusses the major issues raised in the transfer pricing analysis for the multinational pharmaceutical companies in Korea. In this regard, the characteristics of the ethical pharmaceutical industry e.g., products, market, business operations, transfer pricing and medical insurance reimbursement pricing system, are briefly explained first and then analyzed in the context of a transfer pricing analysis. Based on the understanding of such industry characteristics, some of the major issues confronting practitioners in developing a transfer pricing analysis have been identified for more frequently applied transfer pricing methodologies, i.e., (i) the Comparable Uncontrolled Price (CUP) Method and (ii) Resale Price Method (RPM) or Transactional Net Margin Method (TNMM).
First, with regard to the application of the CUP method, there are two major issues: (a) whether a generic product can be treated as comparable to its original product; and (b) if so, whether any differences between an original and its generic products can be reasonably adjusted. There are certainly some clear differences, but it appears practically difficult to quantify and reasonably adjust for the differences between an original and its generic products under the CUP method.
Second, with regard to the application of the RPM or the TNMM, the following issues should be considered: (a) the available categories of comparable companies (pharmaceutical wholesalers vs. pharmaceutical manufacturers) and necessary considerations for product similarity (e.g., pharmaceutical drugs, medical supplies, medical devices, etc.); (b) the nature of secondary manufacturing and the adjustment for the differences in functions performed, customs duty, etc.; (c) accounting and/or structural differences in income statements between multinational and domestic pharmaceutical companies, caused by the medical insurance reimbursement pricing system for generic products, the differences between prescription drugs and OTC drugs, and the difference in product mix among prescription drugs; (d) the level or the nature of R&D activities, and (e) the selection of transfer pricing methodology between the RPM and the TNMM.
After reviewing the relevant issues and based on such discussions, this article emphasizes the importance of industry analysis and concludes with certain suggestions for a reasonable transfer pricing analysis for multinational pharmaceutical companies in Korea.
First, with regard to the application of the CUP method, there are two major issues: (a) whether a generic product can be treated as comparable to its original product; and (b) if so, whether any differences between an original and its generic products can be reasonably adjusted. There are certainly some clear differences, but it appears practically difficult to quantify and reasonably adjust for the differences between an original and its generic products under the CUP method.
Second, with regard to the application of the RPM or the TNMM, the following issues should be considered: (a) the available categories of comparable companies (pharmaceutical wholesalers vs. pharmaceutical manufacturers) and necessary considerations for product similarity (e.g., pharmaceutical drugs, medical supplies, medical devices, etc.); (b) the nature of secondary manufacturing and the adjustment for the differences in functions performed, customs duty, etc.; (c) accounting and/or structural differences in income statements between multinational and domestic pharmaceutical companies, caused by the medical insurance reimbursement pricing system for generic products, the differences between prescription drugs and OTC drugs, and the difference in product mix among prescription drugs; (d) the level or the nature of R&D activities, and (e) the selection of transfer pricing methodology between the RPM and the TNMM.
After reviewing the relevant issues and based on such discussions, this article emphasizes the importance of industry analysis and concludes with certain suggestions for a reasonable transfer pricing analysis for multinational pharmaceutical companies in Korea.
목차
Ⅰ. 서론
Ⅱ. 제약산업의 특성
Ⅲ. 제약산업과 이전가격분석
Ⅳ. 비교가능 제 자 가격방법 적용 관련 논점
Ⅴ. 재판매가격방법 또는 거래순이익률방법 적용 관련 논점
Ⅵ. 결론
〈참고문헌〉
〈Abstract〉
참고문헌 (19)
참고문헌 신청
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
일본의 건강보험 약가 산정기준에 관한 연구
한국병원경영학회지
2009 .01
-
The Optimal Transfer Pricing When There Is No Market
경영논집
1996 .12
-
국제대체가격 결정의 환경요인에 관한 연구
대한경영학회지
1998 .07
-
A Critical Appraisal of Transfer Pricing by Multinational Corporations
유통과학연구
2016 .01
-
Pharmaceutical R&D Project Management under Risk
인하대학교 정석물류통상연구원 학술대회
2009 .10
-
국제대체가격 환경요인이 결정방법의 선택에 미치는 영향
산업경제연구
1999 .08
-
Transfer Pricing for Intangibles
조세학술논집
2016 .06
-
Transfer Pricing for Intangibles
조세학술논집
2016 .06
-
국제이전가격의 결정요인의 분류에 대한 연구
경영경제
2010 .08
-
CASE OF SEOUL PHARMACEUTICAL CO., LTD.
연세경영연구
1970 .06
-
다국적기업의 맥락에서 국제이전가격 결정모형의 확장
대한경영학회지
1999 .07
-
A Study on Distribution System of Pharmaceuticals in the Korea
유통과학연구
2008 .01
-
A Review of Empirical Studies on Transfer Pricing Manipulation
Journal of International Logistics and Trade
2011 .12
-
이전가격 결정의 일곱 단계 접근모형의 연구
경영학연구
1986 .09
-
다국적기업의 이전가격결정에 영향을 미치는 요인과 사례 분석
관리회계연구
2005 .12
-
協議對替價格決定에 관한 實驗硏究
대한경영학회지
1993 .06
-
국제이전가격 결정에 관한 고찰
산업경제연구
2001 .10
-
건강검진 일반수가 비선형가격체계간 이익비교에 관한 연구
보건행정학회지
2008 .01
-
이전가격조정의 관세평가에 관한 연구
관세학회지
2016 .05
이 논문의 저자 정보
이 논문과 함께 이용한 논문
이전가격분석과 비교가능성 요인의 유효성 : 국내 도매업체를 중심으로
최정욱
조세학술논집
2013
.02
K-IFRS의 도입과 적용에 대한 사례연구 : K기업의 사례를 중심으로
이유식
,
홍정화
국제회계연구
2012
.08
동탄2 신도시 제척지역의 주민과 시행사의 이해갈등조정에 관한 사례연구 : 화성시 동탄면 성원아파트를 대상으로
김진경
,
이재준
한국지역개발학회지
2010
.12
역외자산의 정보수집 및 정보교환제도에 관한 고찰
이은미
조세연구
2011
.12
의약(醫藥)에 관한 특허법의 통합적 검토 : 유전자원(遺傳資源)의 문제를 포함하여
박준석
저스티스
2012
.02
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2010-329-003380342